

LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER: STATE-OF-THE-ART MANAGEMENT IN THE NEW CONTINUUM OF CARE

Chairs

Ignacio Duran, Santander, Spain

Thomas B. Powles, London, United Kingdom

SUNDAY, 8 DECEMBER 2024

12:30-14:00 SGT, HALL 407

12:30	Introduction and background of locally advanced and metastatic urothelial cancer	Ignacio Duran, Santander, Spain
12:35	Optimal definition of patient populations: Platinum eligibility and biology-informed science	Thomas B. Powles, London, United Kingdom
12:50	ESMO Guidelines on state-of-the art management of patients with first-line locally advanced and metastatic urothelial cancer and applicability in Asia Pacific	Xinan Sheng, Beijing, China
13:05	Continuum of care after progression on first-line therapy: Testing and rationalising	Ignacio Duran, Santander, Spain
13:20	Optimal management of ADC toxicities in patients with urothelial malignancies	Andrew J. Weickhardt, Heidelberg, VIC, Australia
13:30	Case presentation of a patient with metastatic urothelial cancer: Criteria for choosing the right regimens in first-line and second-line locally advanced and metastatic urothelial cancer	Eun Hee Jung, Seoul, Republic of Korea
13:40	Panel discussion	All speakers
13:55	Summary and conclusion	Thomas B. Powles, London, United Kingdom

This educational activity is provided by ESMO and supported by Astellas.

